Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 18/20 | 0.55 |
| ▸ | EGFR | P00533 | 9/20 | 0.55 |
| ▸ | ABL1 | P00519 | 7/20 | 0.55 |
| ▸ | ABL2 | P42684 | 7/20 | 0.55 |
| ▸ | CDK1 | P06493 | 6/20 | 0.55 |
| ▸ | KDR | P35968 | 5/20 | 0.55 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.51 |
| ▸ | CSK | P41240 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180934 | 1.00 | RIPK2 (0.56) | RIPK2SRCEGFRABL1ABL2 | |
| SCHEMBL30180822 | 0.88 | SRC (0.55) | RIPK2SRCEGFRABL1ABL2 | |
| SCHEMBL23966673 | 0.88 | SRC (0.55) | RIPK2SRCEGFRABL1ABL2 | |
| SCHEMBL20351783 | 0.79 | RIPK2 (0.61) | RIPK2SRC | |
| SCHEMBL7843429 | 0.77 | SRC (0.70) | RIPK2SRCEGFRABL1ABL2 | |
| SCHEMBL23997145 | 0.77 | SRC (0.55) | RIPK2SRCEGFRABL1KDR | |
| SCHEMBL30320501 | 0.77 | SRC (0.55) | RIPK2SRCEGFRABL1KDR | |
| SCHEMBL23966923 | 0.75 | RIPK2 (0.91) | RIPK2SRCEGFRABL1ABL2 | |
| SCHEMBL29998925 | 0.75 | RIPK2 (0.91) | RIPK2SRCEGFRABL1ABL2 | |
| SCHEMBL23966916 | 0.74 | SRC (0.62) | RIPK2SRCEGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091413-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4146348-B1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| CN-115843272-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-4146348-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20220064173-A1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| WO-2021242505-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021242505-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11161852-B1 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161852-B1 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | RIPK2 56/4885SRC 639/4885EGFR 4553/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | RIPK2 56/4885SRC 639/4885EGFR 4553/4885 |
| US-12091413-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | RIPK2 56/4885SRC 639/4885EGFR 4553/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | RIPK2 23/4885SRC 3388/4885EGFR 4872/4885 |
| US-11161852-B1 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | RIPK2 56/4885SRC 639/4885EGFR 4553/4885 |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | RIPK2 56/4885SRC 639/4885EGFR 4553/4885 |
| US-20220064173-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | RIPK2 56/4885SRC 639/4885EGFR 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.